Foralumab was originally discovered and engineered through advanced biotechnology research and is currently developed, formulated, and commercialized primarily by Tiziana Life Sciences. The company collaborates closely with premier academic institutions, such as the Brigham and Women's Hospital neurology research groups, to advance its innovative intranasal delivery formulations. Specialized contract manufacturing organizations are utilized to produce clinical trial supplies under strict regulatory standards.